A Phase 2, Open-label Study of PRAX-944 to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Escalating Multiple Oral Doses in Adults with Generalized Epileptic Syndromes with Absence Seizures
Phase of Trial: Phase II
Latest Information Update: 16 Jul 2019
Price : $35 *
At a glance
- Drugs PRAX-944 (Primary)
- Indications Generalised epilepsy
- Focus Adverse reactions
- Sponsors Praxis Precision Medicines
- 26 Feb 2019 Status changed from not yet recruiting to recruiting.
- 23 Aug 2018 Planned initiation date changed from 16 Jul 2018 to 17 Sep 2018.
- 13 Jun 2018 New trial record